-
Product Insights
NewChronic Idiopathic Myelofibrosis (Primary Myelofibrosis) – Drugs In Development, 2024
Empower your strategies with our Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) – Drugs In Development, 2024 report and make more profitable business decisions. Primary myelofibrosis (PMF) is a rare bone marrow disorder marked by irregularities in blood cell production and the development of fibrous tissue within the bone marrow. Hematopoietic stem cells in the bone marrow, responsible for generating red blood cells, white blood cells, and platelets, undergo DNA changes in PMF, leading to continuous abnormal cell reproduction. Over time, these aberrant...
-
Product Insights
NewPolycythemia Vera – Drugs In Development, 2024
Empower your strategies with our Polycythemia Vera – Drugs In Development, 2024 report and make more profitable business decisions. Polycythemia vera (PV) is a stem cell disorder characterized as a panhyperplastic, malignant, and neoplastic marrow disorder. Symptoms include itchiness, headache, dizziness, weakness, and excessive sweating. The risk of PV increases with age. Treatment includes alkylating agents. The Polycythemia Vera drugs in development market research report provide comprehensive information on the therapeutics under development for Polycythemia Vera, complete with analysis by stage...
-
Product Insights
NewThalassemia – Drugs In Development, 2024
Empower your strategies with our Thalassemia – Drugs In Development, 2024 report and make more profitable business decisions. Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite, and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant. The Thalassemia drugs in development market research report provide comprehensive information on the therapeutics under development for...
-
Product Insights
NewPost-Polycythemia Vera Myelofibrosis (PPV-MF) – Drugs In Development, 2024
Empower your strategies with our Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Drugs In Development, 2024 report and make more profitable business decisions. Post-polycythemia vera myelofibrosis (PPV-MF) is a myeloproliferative blood cancer in which the bone marrow makes too many red blood cells. It may also result in the overproduction of white blood cells and platelets. Symptoms include heart attack, stroke, deep venous thrombosis, headaches, lack of concentration, and fatigue. The disease may be controlled by chemotherapy, transfusions, transplant, and medications. The Post-Polycythemia...
-
Product Insights
NewPost-Essential Thrombocythemia Myelofibrosis (Post-ET MF) – Drugs In Development, 2024
Empower your strategies with our Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) – Drugs In Development, 2024 report and make more profitable business decisions. Post-essential thrombocythemia myelofibrosis (post-ET MF) is a rare, chronic blood disorder characterized by the progression of essential thrombocythemia (ET), a type of myeloproliferative neoplasm (MPN), to myelofibrosis (MF). It represents an advanced stage in the continuum of MPNs, involving abnormal production and functioning of blood cells in the bone marrow. Essential thrombocythemia is characterized by the overproduction of platelets...
-
Product Insights
NewInterstitial Lung Fibrosis – Drugs In Development, 2024
Empower your strategies with our Interstitial Lung Fibrosis – Drugs In Development, 2024 report and make more profitable business decisions. Interstitial Lung Fibrosis or interstitial lung disease (ILD) is a group of diseases that cause scarring of the lungs (fibrosis) or lung parenchyma. If untreated it can lead to respiratory failure and death. Symptoms start with inflammation and can result in bronchiolitis, vasculitis, and alveolitis. Exposure to hazardous chemicals or materials like asbestos, hypersensitivity, drug-induced, underlying autoimmune conditions, family history, smoking,...
-
Product Insights
NewEssential Thrombocythemia – Drugs In Development, 2024
Empower your strategies with our Essential Thrombocythemia – Drugs In Development, 2024 report and make more profitable business decisions. Essential thrombocythemia is a chronic myeloproliferative neoplasm in which cells in the bone marrow that produce the blood cells develop and function abnormally. In essential thrombocythemia, there is mainly an overproduction of platelet-forming cells (megakaryocytes) in the marrow. Symptoms of essential thrombocythemia include headache, dizziness, weakness or numbness on one side of the body, slurred speech, and transient ischemic attacks. The Essential...
-
Product Insights
NewMyelofibrosis – Drugs In Development, 2024
Empower your strategies with our Myelofibrosis – Drugs In Development, 2024 report and make more profitable business decisions. Myelofibrosis is a rare bone marrow disorder where abnormal cells cause fibrous tissue buildup, impairing blood cell production. It's a type of myeloproliferative neoplasm, leading to an enlarged spleen, anemia, fatigue, and increased infection risk. JAK2, MPL, or CALR mutations often underlie this condition. Diagnosis involves blood tests, bone marrow biopsy, and imaging. Treatment aims to manage symptoms and might involve medications, blood...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bomedemstat Tosylate in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bomedemstat Tosylate in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bomedemstat Tosylate in Refractory Acute Myeloid Leukemia Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zalifrelimab in Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zalifrelimab in Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zalifrelimab in Squamous Cell Carcinoma Drug Details: AGEN-1884 (zalifrelimab) is under...